ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its Omnipod® 5 Automated Insulin Delivery (AID) System (Omnipod 5) is now fully available through U.S. retail pharmacy channels for individuals aged six years and older with type 1 diabetes.
“With the significant demand for our tubeless AID system and impressive clinical outcomes, we continue to expand access to Omnipod 5 and provide a best-in-class experience to more people with type 1 diabetes,” said Bret Christensen, Insulet Chief Commercial Officer. “Through our team’s learnings from the limited market release, we have met our timeframe and goals. We are thrilled to announce that Omnipod 5 is now fully available through retail, specialty, and mail-order pharmacies to anyone with a prescription and coverage.”
Omnipod 5 is the first tubeless AID system in the U.S. that integrates with the Dexcom G6 CGM system to help protect against high and low glucose levels1. It is also the only tubeless AID that offers the option of using a compatible smartphone2 or the separate Omnipod 5 Controller, which is provided to every customer. Insulet is continuing to expand its list of compatible smartphones to make this option available to as many people as possible who are living with diabetes.
“Omnipod 5 has been such a life-changing technology. My patients and I have seen significant improvement of their time in range with no overnight lows and much less work required,” said Dr. Anita Swamy, Assistant Professor of Pediatrics, Northwestern Feinberg School of Medicine; Associate Clinician, Pediatric Endocrinology, Ann and Robert H. Lurie Children’s Hospital of Chicago; Medical Director, Chicago Children’s Diabetes Center. “It has given parents and other caregivers more peace of mind, especially overnight, and that’s priceless. People no longer have to make trade-offs between outcomes and a better lifestyle fit because it’s a tubeless AID.” She continued, “Many have told me that they have been extremely happy with Omnipod 5 and are feeling a new sense of freedom. I can see why there has been tremendous demand for this product!”
Marston Alfred, who made the switch to Omnipod 5 from multiple daily injections, said, “Having been on insulin pens for decades, I’ve had to deal with the roller coaster of blood sugar levels. Since starting Omnipod 5 as my first insulin pump, my glucose spikes have disappeared and it’s the first time in my life I’ve had weeks of consistent 80%+ time in range.”
Alfred said he can’t remember the last time he had a low blood sugar, and that his energy and focus have also significantly improved. “It has changed my life,” said Alfred.
Omnipod 5 and Omnipod DASH® are the only insulin pumps available through the pharmacy channel, which eliminates the high upfront cost and four-year lock-in period that is typical with the traditional Durable Medical Equipment (DME) channel, making it simpler for people with type 1 diabetes to access.
To expand awareness of Omnipod 5 as the first tubeless AID system in the U.S., Insulet has launched new direct to consumer TV advertising, in addition to its ongoing digital and social campaigns.
For more information or to get started, visit the Omnipod website.
About Insulet Corporation:
Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet’s latest innovation, the Omnipod 5 Automated Insulin Delivery System, is a tubeless automated insulin delivery system, integrated with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks3, and is fully controlled by a compatible personal smartphone. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, please visit: insulet.com and omnipod.com.
Forward-Looking Statement:
This press release may contain forward-looking statements concerning Insulet's expectations, anticipations, intentions, beliefs, or strategies regarding the future. These forward-looking statements are based on its current expectations and beliefs concerning future developments and their potential effects on Insulet. There can be no assurance that future developments affecting Insulet will be those that it has anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond its control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements, and other risks and uncertainties described in its Annual Report on Form 10-K, which was filed with the Securities and Exchange Commission on February 24, 2022 in the section entitled "Risk Factors," and in its other filings from time to time with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should any of its assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Insulet undertakes no obligation to publicly update or revise any forward-looking statements.
1 Study in 240 people with T1D aged 6 - 70 years involving 2 weeks standard diabetes therapy followed by 3 months Omnipod 5 use in Automated Mode. Average time with high blood glucose in adults/adolescents and children, standard therapy vs. 3-month Omnipod 5: 32.4% vs. 24.7%; 45.3% vs. 30.2%. Median time with low blood glucose in adults/adolescents and children, standard therapy vs. 3-month Omnipod 5: 2.0% vs. 1.1%; 1.4% vs. 1.5%. Brown et al. Diabetes Care (2021).
2 For a list of compatible smartphone devices, visit omnipod.com/compatibility.
3 If a user’s glucose alerts and readings from the G6 do not match symptoms or expectations or a user is taking over the recommended maximum dosage amount of 1,000mg of acetaminophen every six hours, one should use a blood glucose meter to make diabetes treatment decisions.
©2022 Insulet Corporation. Omnipod, Omnipod DASH, and Omnipod 5 are trademarks or registered trademarks of Insulet Corporation in the United States of America and other various jurisdictions. All rights reserved. Dexcom G6 is a registered trademark of Dexcom and used with permission. All other trademarks are the property of their respective owners. The use of third-party trademarks does not constitute an endorsement or imply a relationship or other affiliation.
